Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

Peter B. Gilbert1,2,26✉, Yunda Huang1,3,26✉, Allan C. deCamp1, Shelly Karuna2, Yuanyuan Zhang1, Craig A. Magaret1, Elena E. Giorgi4,24, Bette Korber4, Paul T. Edlefsen1, Raabia Rossenkhan1, Michal Juraska6, Erika Rudnicki5, Nidhi Kochar1,3,14, Yuanyuan Zhang1, Erika Rudnicki1, Nidhi Kochar1, Ying Huang1, Lindsay N. Carpp1,2,26, Magdalena E. Sobieszczyk1,2, Nigel Garrett19, James I. Mullins3,20,21, Daniel B. Reeves4, Paul T. Edlefsen1,21,23, David C. Montefiori1, Dan H. Barouch4

The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show that the predicted serum neutralization 80% inhibitory dilution titer (PT80) biomarker—which quantifies the neutralization potency of antibodies in an individual’s serum against an HIV-1 isolate—can be used to predict HIV-1 prevention efficacy. Similar to the results of nonhuman primate studies, an average PT80 of 200 (meaning a bnAb concentration 200-fold higher than that required to reduce infection by 80% in vitro) against a population of probable exposing viruses was estimated to be required for 90% prevention efficacy against acquisition of these viruses. Based on this result, we suggest that the goal of sustained PT80 >200 against 90% of circulating viruses can be achieved by promising bnAb regimens engineered for long half-lives. We propose the PT80 biomarker as a surrogate endpoint for evaluation of bnAb regimens, and as a tool for benchmarking candidate bnAb-inducing vaccines.

Most licensed antiviral vaccines prevent infection or disease primarily through eliciting antibodies that block acquisition or replication and, for several of these vaccines, neutralizing antibody (nAb) titer was established as a correlate of protection or surrogate endpoint1. A successful HIV vaccine will also probably need to generate bnAbs. Global efforts to meet the formidable scientific challenge of developing such an HIV vaccine1 would benefit greatly from a validated nAb titer correlate of protection1,3. The nonhuman primate (NHP) SHIV (simian-HIV) challenge model laid groundwork for this validation by showing that serum nAb titer is a correlate of protection from SHIV acquisition, in a meta-analysis of NHPs administered a single bnAb4, and also in NHPs immunized with recombinant native-like HIV-1 Envelope trimers5.

The Antibody Mediated Prevention (AMP) trials (NCT02716675 and NCT02568215) of the intravenously (IV) administered CD4 binding site (CD4bs)-targeting bnAb VRC01 assessed HIV-1 prevention efficacy (PE), defined as the percentage reduction (VRC01 versus placebo) in the risk of HIV-1 acquisition over 80 weeks6.

1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. 2Department of Biostatistics, University of Washington, Seattle, WA, USA. 3Department of Global Health, University of Washington, Seattle, WA, USA. 4Los Alamos National Laboratory, Los Alamos, NM, USA. 5Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA. 6Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA. 7National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa. 8Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 9Department of Surgery, Duke University Medical Center, Durham, NC, USA. 10Duke University Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke Center for Human Systems Immunology, Durham, NC, USA. 11Family Health International, Durham, NC, USA. 12Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA. 13Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa. 14Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa. 15Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Universidad Nacional Mayor de San Marcos, Lima, Peru. 16Division of Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 17Botswana-Harvard AIDS Initiative Partnership for HIV Research and Education, Gaborone, Botswana. 18Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, MA, USA. 19Division of Medical Virology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. 20Department of Microbiology, University of Washington, Seattle, WA, USA. 21Department of Medicine, University of Washington, Seattle, WA, USA. 22Institute of Global Health and Infectious Diseases, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 23Department of Laboratory Medicine, University of Washington, Seattle, WA, USA. 24Present address: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. 25Present address: Duke Center for Human Systems Immunology, Duke University Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Durham, NC, USA. 26These authors contributed equally: Peter B. Gilbert, Yunda Huang. ✉e-mail: pgilbert@fredhutch.org

1924
Neutralization sieve analysis showed that PE is strongly dependent on the neutralization sensitivity of an HIV-1 isolate to VRC01, measured as in vitro 80 or 50% inhibitory concentration (IC₈₀ or IC₅₀, respectively). In particular, statistical tests showed that PE is significantly greater against viruses with lower IC₈₀ or lower IC₅₀, and the result was replicated across each of the individual AMP trials in two distinct cohorts. In HVTN 704/HPTN 085 (704/085), which enrolled 2,699 transgender individuals and men who have sex with men in Brazil, Peru and the United States, PE was 73.0% (95% confidence interval (CI) 27.6–89.9%) against viruses with IC₈₀ < 1 µg/ml⁻¹. Moreover, in HVTN 703/HPTN 081 (703/081), which enrolled 1,924 heterosexual women in Botswana, Kenya, Malawi, Mozambique, South Africa, Tanzania and Zimbabwe, PE was 78.6% (95% CI 17.3–94.4%) against viruses with IC₈₀ < 1 µg/ml⁻¹.

In each trial, PE was near zero for viruses with IC₈₀ > 1 µg/ml⁻¹.

The parameter IC₈₀ is a neutralization property of a given antibody clinical lot against a given HIV-1 pseudovirus in vitro. In the absence of a validated nAb titer correlate of protection, summary measures (for example, geometric mean) of a bnAb IC₈₀ against each pseudovirus in a panel likely to reflect circulating HIV-1s have been used to predict bnAb prevention potential. For example, geometric mean IC₈₀ and the percentage of viruses neutralized at a specific IC₈₀ cutoff (that is, neutralization breadth in vitro) against a panel of representative HIV-1 pseudoviruses have been used to help identify the most promising bnAbs, multispecific bnAbs and bnAb combinations to advance into clinical trials for their potential to achieve high prevention efficacy. However, because IC₈₀ contains no information about the concentration of bnAb in an individual’s sera it is therefore not sufficient to quantify the ability of that individual’s blood to neutralize an exposing virus at a given time because antibody concentration changes over time after administration. Logically, both time-varying bnAb concentration and bnAb potency/breadth, as quantified by distributions of IC₈₀, might be required to estimate prevention efficacy. Certain mathematical combinations of these quantities (for example, refs. 9,10) have been assumed to be correlates of prevention efficacy in previous modeling studies.

In this work, we analyzed a nAb titer biomarker that integrates IC₈₀ with serum bnAb concentration, PTₘₐₓ, of a VRC01 recipient’s serum at a given time to a given reference virus as a correlate of VRC01 prevention efficacy in the AMP trials. Figure 1 depicts how serum at a given time to a given reference virus as a correlate of VRC01 prevention efficacy in the AMP trials. (that is, participants with confirmed acquisition of HIV-1 infection after enrollment and by the week 80 visit), a similar result was observed in sera obtained at the study visit (and, for a subset, from the last two study visits) immediately before the first positive HIV-1 RNA PCR test, when assayed against autologous isolates (Fig. 2).

PTₘₐₓ associated with VRC01 prevention efficacy. To define the level of VRC01 serum neutralization that correlates with reduced HIV-1 acquisition in AMP, we first used the median VRC01 serum concentration (calculated as the median observed VRC01 concentration at all mid-infusion visits across all noncases in the case-control samples) and the IC₈₀ of the acquired virus to estimate how VRC01 PE varied with PTₘₐₓ against the autologous virus. Achieving 50, 75 and 90% PE required PTₘₐₓ values of 32, 82 and 194, respectively; these titers were higher than those needed to achieve the same level of protection in the NHP high-dose challenge model (8, 32 and 83, respectively) (Fig. 3). These protection-by-PTₘₐₓ curves looked similar in two different sensitivity analyses of the NHP challenge model data, where bnAb and/or SHIV challenge virus data with outlying protection curves were excluded (figure 2 of ref. 1; Extended Data Fig. 1).

Population-level PTₘₐₓ correlate of protection. The above estimates, which use a representative VRC01 serum concentration (median), are imprecise given that individual VRC01 concentrations at HIV-1 acquisition differ from this representative concentration. Supporting an alternative approach, the even spread of estimated infection dates across infusion intervals in placebo recipients (Extended Data Fig. 2) suggested that HIV-1 exposures occurred approximately uniformly over time. When population pharmacokinetics (popPK) modeling—which incorporates data from all individuals in a given cohort to study PK at the population level—was used to estimate daily VRC01 concentrations, PTₘₐₓ values were markedly higher against sensitive versus resistant placebo recipient-acquired viruses (taken to be representative of strains circulating in the trial settings); median over days and viruses (interquartile range) PTₘₐₓ was 41.3 (16.3–112.0) against IC₈₀ < 1 µg/ml⁻¹ virus, 9.6 (4.1–23.7) against IC₈₀ 1–3 µg/ml⁻¹ virus and 1.3 (0.3–4.3) against IC₈₀ > 3 µg/ml⁻¹ virus (Fig. 4). Notably, for virus sensitivity categories 1–3 and > 3 µg/ml⁻¹, many PTₘₐₓ values fell below the limit of detection of the TZM-bl target cell neutralization assay (titer = 10) and, in the >3 µg/ml⁻¹ category, nearly half the PTₘₐₓ values were <1.0 (although PTₘₐₓ values <1.0 can be predicted, they were not experimentally tested, which would require concentration of serum).

Low PTₘₐₓ values against autologous virus at HIV-1 acquisition. If serum VRC01 neutralization titer is a true correlate of prevention efficacy, then PTₘₐₓ values of VRC01-recipient noncases (their individual-specific median PTₘₐₓ values over follow-up) against viruses acquired by placebo recipients must therefore be higher than those of VRC01-recipient cases at acquisition against autologous viruses (assuming that exposures to HIV-1 occur approximately uniformly over time). Noncases are defined as participants who completed the week 88 visit without HIV-1 infection diagnosis. We found that, indeed, autologous PTₘₐₓ values were higher in VRC01-recipient noncases, with a geometric mean of 4.3 (95% CI 4.0–4.7) compared with a geometric mean of 1.5 (95% CI 0.9–2.4) in VRC01-recipient cases, a ratio of 2.9 (95% CI 1.8–4.8, P < 0.001); similar results were obtained for individual dose arms (Figs. 5 and Methods). In these calculations, each individual’s HIV-1 acquisition date was derived by a Bayesian procedure that combines an estimate obtained by fitting a Poisson distribution to the gag–pol–nef sequences from the first RNA PCR-positive time point with
Calculation of predicted serum ID₈₀ titer (PT₈₀) for a bnAb against a reference virus:

\[
\text{Serum bnAb concentration} \times \left( \frac{1}{\text{Clinical lot bnAb IC}_{80} \text{ against a reference virus}} \right) = \text{PT}_{80}
\]

Examples:

\[
\begin{align*}
20 \mu g/ml^{-1} \times \frac{1}{20 \mu g/ml^{-1}} &= 10 \\
50 \mu g/ml^{-1} \times \frac{1}{20 \mu g/ml^{-1}} &= 25 \\
100 \mu g/ml^{-1} \times \frac{1}{20 \mu g/ml^{-1}} &= 50
\end{align*}
\]

Calculation of PT₈₀ for a bnAb against an exposing virus population:

\[
\text{Average bnAb serum concentration over follow-up} \times \left( \frac{1}{\text{Average bnAb IC}_{80} \text{ against exposing virus population}} \right) = \text{Average PT}_{80}
\]

Examples:

\[
\begin{align*}
20 \mu g/ml^{-1} \times \frac{1}{4.0 \mu g/ml^{-1}} &= 5 \\
50 \mu g/ml^{-1} \times \frac{1}{2.0 \mu g/ml^{-1}} &= 25 \\
100 \mu g/ml^{-1} \times \frac{1}{1.0 \mu g/ml^{-1}} &= 100
\end{align*}
\]

A combination regimen of these bnAbs would have an average combination PT₈₀ of 198, based on the individual bnAb average PT₈₀s and the Bliss–Hill model.

Fig. 1 | Visual representation of how two independent pieces of information (serum bnAb concentration at a given time point and neutralization sensitivity of a target virus to the bnAb (IC₈₀)) are used to calculate the PT₈₀ biomarker. a. Formula for calculation of PT₈₀ for a bnAb against a target virus. IC₈₀ for a clinical lot bnAb product against a target virus, as determined by the TZM-bi target cell assay, is the bnAb concentration needed for 80% reduction in RLU compared with target virus control wells after subtraction of background RLU. Based on the PT₈₀ biomarker, increasing bnAb serum concentration and increasing target virus sensitivity (that is, decreasing IC₈₀) have an equal impact on increasing PT₈₀ and hence improvement in potential prevention efficacy. b, Example calculations showing how PT₈₀ against a target virus differs for three different bnAbs sharing the same IC₈₀ against the target virus yet are present at different serum concentrations. A similar result would be obtained (differing PT₈₀ values) if the same bnAb was present at three different serum concentrations. c, Adaptation of the formula shown in a to a scenario where average PT₈₀ is calculated against a population of exposing viruses. d, Example calculations of average PT₈₀ over a follow-up period against an exposing virus population for three different bnAbs. The yellow bnAb has characteristics of VRC01 observed in the AMP trials (average serum concentration over VRC01 recipients and over 80 weeks of follow-up 20 µg/ml¹), average IC₈₀ of exposing viruses 4.0 µg/ml¹, which is calculated as the weighted average of the three IC₈₀s: for example, (0.5 µg/ml¹) × 0.30 + (2.0 µg/ml¹) × 0.15 + (6.5 µg/ml¹) × 0.55 = 4.0 µg/ml¹. If IC₈₀ is used for comparison of the yellow and blue bnAbs, the results indicate that the blue bnAb is twofold better than the yellow in regard to its potential prevention efficacy, whereas if PT₈₀ is used for comparison the blue bnAb is fivefold better than the yellow. The PT₈₀ biomarker is superior on account of its enhanced measurement of neutralization potency against anticipated exposing viruses.

VRC01 serum concentration is a correlate of risk. We next assessed VRC01 serum concentration as a correlate of risk of instantaneous HIV-1 acquisition using a Cox model, including all VRC01-recipient cases and randomly sampled noncases. The estimated hazard ratio of HIV-1 acquisition per tenfold increase in date-of-acquisition serum VRC01 concentration was 0.53 (95% CI 0.31–0.92, P = 0.02). The fact that the AMP trials randomized VRC01 at two doses provided the opportunity to confirm that this correlate of risk result was consistent with the observed dose effect.
on HIV-1 acquisition. Affirmatively, the 30 mg kg\(^{-1}\) arm had 23% improved efficacy compared with the 10 mg kg\(^{-1}\) arm\(^{32}\) (calculation shown in Methods) and the 30 mg kg\(^{-1}\) arm had 2.4-fold higher median mid-infusion visit serum VRC01 concentration than the 10 mg kg\(^{-1}\) arm, where the correlate of risk result yielded 25% risk reduction per 2.4-fold increase in concentration.

**Prediction of prevention efficacy of a triple-bnAb regimen.** Various bnAb combinations and bispecific Abs, enabling consecutive targeting of different epitopes, are in clinical development for HIV-1 prevention\(^{16,17}\). Predicted potency-breadth curves have suggested that a triple combination consisting of one CD4bs-targeting bnAb, one V2 glycan-targeting bnAb and one V3 glycan-targeting bnAb would have the best neutralization coverage against a panel of clade C viruses\(^{7}\). One such combination, VRC07-523LS (CD4bs), PGT121 (V3 glycan) and PGDM1400 (V2 glycan), has been predicted to have 99% neutralization breadth (IC\(_{80}\) of clade C viruses\(^{7}\)). One such combination, VRC07-523LS (CD4bs), PGT121 (V3 glycan) and PGDM1400 (V2 glycan), has been predicted to have 99% neutralization breadth (IC\(_{80}\) of clade C viruses\(^{7}\)).

16 weeks were simulated based on popPK modeling (Methods). Because data from the LS forms of PGT121 and PGDM1400 are not yet available, the predictions considered a possible increase of 2.5-fold in elimination half-life conferred by the LS mutation, with 2.5-fold being a conservative assumption based on the previously reported fourfold increase\(^{30}\). Our results suggest that PT\(_{80}\) > 200 of a bnAb regimen to a given exposing virus would provide 90% or higher efficacy to block HIV-1 acquisition with that virus. We applied this threshold (PT\(_{80}\) > 200) in our definition of neutralization coverage. Neutralization coverage by at least one bnAb in the regimen, averaged over time for a 16-weekly regimen, and to the 47 viruses (all subtype C) acquired by 29 placebo recipients from 703/081 was 71%; neutralization coverage averaged over time and to the 70 viruses (90% subtype B) acquired by 35 placebo recipients from 704/085 was 73% (Fig. 6a,b). In contrast, neutralization coverage of VRC01 (at 30 mg kg\(^{-1}\)) averaged over time and to the 704/085 viruses was 8%.

We then applied the relationship between PT\(_{80}\) and PE (Fig. 3 and Methods) in our prediction of PE. Predicted prevention efficacy of the triple-bnAb regimen at 20 mg kg\(^{-1}\) each, administered every 16 weeks, was 91% (95% CI: 86%, 94%) against the 47 clade C viruses
and 92% (95% CI: 87%, 96%) against the 70 predominantly clade B viruses (Fig. 6c,f). For the triple-bnAb regimen at 40 mg kg\(^{-1}\) each, the predicted prevention efficacy was 95% (95% CI: 92%, 97%) and 96% (95% CI: 92%, 98%), respectively. Extended Data Fig. 3 shows analogous 24-week plots for the LS bnAb versions, indicating about 87% predicted efficacy. As internal validation, the predicted prevention efficacy of the VRC01 30 mg kg\(^{-1}\) regimen used in AMP was 26 and 32% against the clade C viruses and the predominantly clade B viruses, respectively, which matches closely the observed prevention efficacy of 27 and 31% (ref. 6). Had the AMP VRC01 regimen been administered at 40 mg kg\(^{-1}\) every 16 weeks, predicted prevention efficacy would have been 79% (68%, 86%) against the clade C viruses and 89% (79%, 94%) against the predominantly clade B viruses. This modeling suggests that combination bnAb regimens are needed for high prevention efficacy.

The same analyses were performed for predicted serum neutralization 50% inhibitory dilution titer (PT\(_{50}\)) defined in the analogous way, using IC\(_{50}\) rather than IC\(_{80}\), and the results and conclusions were similar (Extended Data Figs. 4–9).

**Discussion**

This study advances the PT\(_{50}\) biomarker as a probable surrogate endpoint for HIV-1 acquisition. By estimation of which serum bnAb titers will be protective for humans in the prevention of HIV-1 acquisition, regardless of clade, sex or route of infection, these findings address the critical need to establish targets for future preclinical and clinical expectations, for both passive instillation of bnAb combinations and active administration of any candidate HIV-1 vaccine. Notably, the neutralization titers suggested by data from the AMP trials are necessary for high PE (approximately 200 for 90% prevention efficacy, similar to that reported in NHP\(^{6}\)) should be achievable. Crucial for meeting this goal will be the use of bnAb combinations, some of which are now advancing to clinical testing (for example, PGDM1400LS + PGT121.414LS + VRC07–523LS), which have been engineered to have increased half-lives (LS versions) and improved in vitro neutralization. The PT\(_{50}\) correlate can be used for systematic comparison and down-selection of candidate bnAb combinations in development\(^6,11\). We estimate through modeling that the PGDM1400LS + PGT121.414LS + VRC07–523LS combination will provide levels of HIV prevention efficacy that greatly exceed those of VRC01, from 29 to 90% (that is, 7.3-fold higher efficacy). Subcutaneous administration, and the possibility of more frequent dosing, could also help maintain higher bnAb titers.

Modeling of vaccine prophylaxis versus passive infusion prophylaxis requires different considerations, because a candidate bnAb-inducing vaccine would induce a polyclonal bnAb response. Despite this difference, the approach to prediction of prevention efficacy based on serum neutralization titers against anticipated exposing viruses over time is applicable to both prevention modalities. For example, for candidate bnAb-inducing vaccines, the primary immunogenicity endpoint of a vaccine study could be the magnitude–breadth of directly measured serum ID\(_{50}\) titers against a panel of viruses representing the antigenic distribution of strains circulating in a given geographic region/population of interest, averaged over a given follow-up period. Combining these magnitude–breadth data with antibody decay longitudinal mixed-effects models (for example, those in ref. 22) would allow prediction of vaccine efficacy during the follow-up period. However, for passive antibody prophylaxis PT\(_{50}\) would be used because the ability to accurately model bnAb concentrations over time pharmacokinetically enables effective use of this biomarker that is much easier to use than ID\(_{50}\).

Another key future potential application of the PT\(_{50}\) correlate is in provisional and traditional approval decisions for bnAb combination regimens (and, later, potentially bnAb-inducing vaccines). The framework is also broadly applicable—for example, rapid adaptation of the pseudovirus-based HIV-1 neutralization assay to COVID-19...
VRC01 PT80 values against autologous (case) or placebo (noncase) virus isolates

- VRC01 pooled, (noncase)/case
- VRC01 30 mg kg$^{-1}$, (noncase)/case
- VRC01 10 mg kg$^{-1}$, (noncase)/case
- VRC01 pooled, case
- VRC01 pooled, noncase
- VRC01 30 mg kg$^{-1}$, case
- VRC01 30 mg kg$^{-1}$, noncase
- VRC01 10 mg kg$^{-1}$, case
- VRC01 10 mg kg$^{-1}$, noncase

Geometric mean of PT80 and ratios (95% CI)

- VRC01 case
- VRC01 noncase
- (VRC01 noncase)/VRC01 case
vaccine studies helped provide evidence for establishing a neutralizing antibody surrogate endpoint for COVID-19 vaccines\textsuperscript{21-26}—with applications including a noninferiority, neutralization-based endpoint approach to support vaccine emergency use authorization or approval\textsuperscript{27,28}. Moreover, our findings\textsuperscript{23} are informing policy decisions (for example, on boosters) and will potentially aid design of future trials, including those of pan-coronavirus vaccines. The near-simultaneous validation of a pseudovirus-based neutralization assay for these two different pathogens (HIV-1 and SARS-CoV-2) is an exciting step forward in biomarker science, and we anticipate that our PT\textsubscript{80} correlate described here will have similar utility in the HIV prevention field.

It is important to note that immune markers can be useful as correlates of protection (that is, reliably predictive of prevention efficacy) even if they are not a mechanistic correlate of protection (defined in ref. \textsuperscript{29} as “the immune response that is responsible for protection”). For example, there are several approved vaccines for which a nonmechanistic correlate of protection is accepted as a surrogate endpoint for regulatory decisions\textsuperscript{30-32}. It is advantageous to use a serum marker as the correlate of protection for ease of use (for example, avoidance of invasive mucosal sampling). However, in general, for a biomarker like PT\textsubscript{80}—that is, one that statistically correlates with protection yet is measured in serum and is thus less likely to be a mechanistic correlate of protection for a sexually transmitted infection (HIV) compared with another biomarker such as PT\textsubscript{80} in mucosal tissues—it is important to study its correlation with the more mechanistic biomarker. For IV administered VRC01, strong positive associations have been reported between serum versus rectal mucosal levels\textsuperscript{33} whereas further work with larger sample sizes may be needed to better understand the extent of correlation between serum versus vaginal mucosal levels. Further research is also needed to characterize neutralization activity in serum versus tissues of virus entry among mAb recipients.

The correlations of PT\textsubscript{80} (or PT\textsubscript{50}) with prevention efficacy in the AMP trials versus the NHP model are similar\textsuperscript{1} with the caveat that we estimated/modelled population-level PE as a function of PT\textsubscript{80} in the AMP trials whereas the NHP challenge models estimated/modelled per-challenge-level PE (Fig. 3). There has been concern that the high-dose rectal challenge NHP model, which is designed to infect all animals after one exposure, may overestimate the required titer needed to protect humans from sexual exposure to HIV, who demonstrate low per-exposure risk for infection (around 0.4–1.0%); even low-titer, repeat-dose NHP challenge models infect up to 30% of animals per challenge. However, our results suggest that the NHP model did not yield a biased overestimate. Moreover, our results caution that low-dose NHP challenge models could overestimate prevention efficacy. Nevertheless, studies of vaccinated NHP showed that protection against autologous virus requires high titers of tier 2 polyclonal neutralizing antibodies\textsuperscript{1}. This is in line with the AMP trial indicating that high titers of bnAbs are apparently required for protection. Collectively, these findings pose a major challenge to the development of HIV-1 vaccines expected to depend on stimulation of bnAb formation, and highlight a need to increase vaccine-elicited bnAb levels and improve their durability.

Two analyses of the AMP trial data—a neutralization sieve analysis and a correlate of risk analysis—mutually support the PT\textsubscript{80} biomarker as a correlate of protection and as a key biomarker for modeling predicted bnAb prevention efficacy. Neutralization sieve analysis showed that prevention efficacy decreased with increasing virus IC\textsubscript{80} because estimated PE was 4.5-fold higher against viruses tenfold more sensitive to VRC01 neutralization (81.6% against viruses with IC\textsubscript{80} = 0.2 μg ml\textsuperscript{-1} versus 16.5% against viruses with IC\textsubscript{80} = 2 μg ml\textsuperscript{-1})\textsuperscript{34}. Correlate of risk analysis estimated that HIV-1 acquisition risk of VRC01 recipients was 2.1-fold lower for every tenfold increase in VRC01 serum concentration at exposure. Our model of PE based on the PT\textsubscript{80} biomarker posits that a change in either VRC01 concentration against an exposing virus, or IC\textsubscript{80} of the exposing virus, translates to the same impact on PE—for example, increasing concentration tenfold or decreasing IC\textsubscript{80} tenfold would alter PE by the same amount. The fact that the IC\textsubscript{80} effect of 4.5 exceeded the ‘concentration effect’ of 2.1 suggests deviation from this model. However, this result is expected if in fact the model holds, because there is uncertainty in the estimation of HIV-1 acquisition dates. The uncertainty in the actual date of infection biased the estimate of the concentration effect toward 1.0, which is so-called biasing-towards-the-null caused by random/un systematic measurement error (for example, ref. \textsuperscript{29} in the statistics literature), indicating that 2.1 is an underestimate. In contrast, neutralization sieve analysis did not use estimated infection dates and thus is not subject to this attenuating bias. Therefore, the results are consistent with our model for prediction of bnAb regimen PE, which posits that PE can be improved equally by increasing either bnAb concentration or neutralization sensitivity. Note that the AMP trials did not use an LS-modified bnAb; estimations of concentrations at the true acquisition dates would be more accurate for an LS bnAb, because these have a prolonged elimination phase with serum concentrations decaying slowly.

Both IC\textsubscript{80} and VRC01 concentration varied markedly in AMP: the IC\textsubscript{80} of acquired viruses ranged from 0.07 to >10 μg ml\textsuperscript{-1} (the assay’s lower limit of quantification) and the highest observed concentration in the AMP trial was 278 μg ml\textsuperscript{-1} (5 days post-infusion 2, 30 mg kg\textsuperscript{-1} arm). This dynamic range is key for discerning correlates. However, one limitation of our analysis is that the challenges of infection timing estimation constrain the ability of the concentration correlates analysis to fully leverage concentration variability. In contrast, the fact that neutralization sieve analysis does not rely upon infection time estimation (and accounts for the full range of IC\textsubscript{80} values) renders it more sensitive for characterization of correlates than concentration correlates analysis.

A further limitation of this correlates study in regard to making progress toward validation of the PT\textsubscript{80} biomarker is that we...
HVTN 703/HPTN 081 (m = 47 virus isolates)

- **Coverage: IV PGT121 + PGDM1400 + VRC07-523LS 20 + 20 + 20 mg kg\(^{-1}\) (1-active)
- **Coverage: IV PGT121 + PGDM1400 + VRC07-523LS 20 + 20 + 20 mg kg\(^{-1}\) (2-active)
- **Coverage: IV PGT121 + PGDM1400 + VRC07-523LS 20 + 20 + 20 mg kg\(^{-1}\) (3-active)

HVTN 704/HPTN 085 (m = 70 virus isolates)

- **Coverage: IV PGT121 + PGDM1400 + VRC07-523LS 20 + 20 + 20 mg kg\(^{-1}\) (1-active)
- **Coverage: IV PGT121 + PGDM1400 + VRC07-523LS 20 + 20 + 20 mg kg\(^{-1}\) (3-active)
- IV VRC01 30 mg kg\(^{-1}\)

**Average coverage (%) through first 8 weeks**

- 1-active: 78, 74, 71
- 2-active: 42, 39, 36
- 3-active: 13, 12, 10
- VRC01: 8, 10, 8

**Average coverage (%) through first 12 weeks**

- 1-active: 83, 78, 73
- 2-active: 40, 36, 32
- 3-active: 8, 6, 6
- VRC01: 8, 10, 8

**Average coverage (%) through first 16 weeks**

- 1-active: 8, 10, 8
- 2-active: 40, 36, 32
- 3-active: 8, 6, 6
restricted to the VRC01 antibody. Our prediction modeling of prevention efficacy for antibody regimens involving other antibodies besides VRC01 (some of which are in different epitope classes than CD4bs antibodies) assumes transportability of the PT$_{so}$ biomarker correlate learned from VRC01 to the PT$_{mo}$ biomarker for other antibodies and antibody combinations. More specifically, our prevention efficacy modeling exercise assumes that the mathematical relationship of per-exposure prevention efficacy with the PT$_{so}$ biomarker level would be the same for other antibodies or antibody combinations. Transportability assumptions may be more credible within an epitope class than across different epitope classes.

Another limitation is that AMP studied PE and correlates for the outcome of HIV-1 diagnosis, not for infection of a single cell, which is not fully observable. Virus features (IC$_{80}$ genotypes) were measured from the first available HIV RNA-positive detection in plasma. Open questions include: were viruses present in hidden compartments before detectability along with delayed seroconversion? What were their features? Did the presence of VRC01 result in subclinical acquisition of HIV?

Cumulatively, our results demonstrate the utility of the pseudovirus-based neutralization assay in infectious disease research more generally, and advance the PT$_{so}$ biomarker toward use as a correlate of protection for future HIV-1 bnAb combination trials or bnAb-inducing vaccine trials.

**Online content**

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41591-022-01953-6.

Received: 16 November 2021; Accepted: 14 July 2022; Published online: 22 August 2022

**References**

1. Plotkin, S. A. Correlates of protection induced by vaccination. *Clin. Vaccin. Immunol.* **17**, 1055–1065 (2010).
2. Bekker, L. G. et al. The complex challenges of HIV vaccine development require renewed and expanded global commitment. *Lancet* **379**, 384–388 (2020).
3. Plotkin, S. A. & Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. *Clin. Infect. Dis.* **54**, 1615–1617 (2012).
4. Pegu, A. et al. A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge. *Cell Host Microbe* **26**, 336–346 (2019).
5. Pauwther, M. G. et al. Vaccine-induced protection from homologous Tier 2 SHIV challenge in nonhuman primates depends on serum-neutralizing antibody titers. *Immunity* **50**, 241–252 (2019).
6. Corey, L. et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. *N. Engl. J. Med.* **384**, 1003–1014 (2021).
7. Wagh, K. et al. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 Clade C infection. *PLoS Pathog.* **12**, e1005520 (2016).
8. Wagh, K. et al. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. *PLoS Pathog.* **14**, e1006860 (2018).
9. Reeves, D. B. et al. Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. *PLoS Comput. Biol.* **16**, e1007626 (2020).
10. Mayer, B. T. et al. Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention. *PLoS Comput. Biol.* **18**, e1001003 (2022).
11. Huang, Y. et al. Brief report: prediction of serum HIV-1 neutralization titers after passive administration of VRC01. *J. Acquir Immune Defic. Syndr.* **83**, 434–439 (2020).
12. Huang, Y. et al. Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. *Hum. Vaccines Immunother.* https://doi.org/10.1080/21645515.2021.1908030 (2021).
13. Giorgi, E. E. et al. Estimating time since infection in early homogeneous HIV-1 samples using a Poisson model. *BMC Bioinformatics* **11**, 532 (2010).
14. Grebe, E. et al. Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool. *BMC Infect. Dis.* **19**, 894 (2019).
15. Gilbert, P. B., Zhang, Y., Radnicki, E. & Huang, Y. Assessing pharmacokinetic marker correlates of outcome, with application to antibody prevention efficacy trials. *Stat. Med.* **38**, 4503–4518 (2019).
16. Karuna, S. T. & Corey, L. Broadly neutralizing antibodies for HIV prevention. *Annu. Rev. Med.* **71**, 329–349 (2020).
17. Stephenson, K. E., Wagh, K., Korber, B. & Barouch, D. H. Vaccines and broadly neutralizing antibodies for HIV-1 prevention. *Annu. Rev. Immunol.* **38**, 673–703 (2020).
18. Jüd, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. *Nat. Med.* **27**, 1718–1724 (2021).
19. Gaudinski, M. R. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VIRG01: a Phase 1 open-label clinical trial in healthy adults. *PLoS Med.* **15**, e1002493 (2018).
20. Cohen, Y. Z. et al. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: a randomized, phase 1 study. *PLoS ONE* **14**, e0219142 (2019).
21. Amanja, I. J., Carlson, N. E. & Silka, M. K. Duration of humoral immunity to common viral and vaccine antigens. *N. Engl. J. Med.* **357**, 1903–1915 (2007).
22. Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science* **375**, 43–50 (2022).
23. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat. Med.* **27**, 1205–1211 (2021).
24. Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine* **39**, 4423–4428 (2021).
25. Fong, Y. et al. Immune correlates analysis of a single Ad26.COV2.S dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial. 10.1101/2022.04.06.22227763 Preprint at https://doi.org/10.1101/2022.04.06.22227763 (2022).
26. Wahl, E. B. et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. *N. Engl. J. Med.* **386**, 35–46 (2022).
27. Emergency Use Authorization for Vaccines to Prevent COVID-19 (US Food and Drug Administration, 2022); https://www.fda.gov/media/142749/download
28. Plotkin, S. A. & Gilbert, P. in *Plotkin's Vaccines* 7th edn (eds Plotkin, S. A. et al.) 35–40 (Elsevier, 2018).
29. Astronomo, R. D. et al. Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. *J. Clin. Invest.* https://doi.org/10.1172/JCI146975 (2021).
30. Burton, D. R. Amping up HIV antibodies. *Science* **372**, 1397–1398 (2021).
31. Carroll, R. J., Ruppert, D., Stefanikia, L. A. & Crainicenaa, C. M. Measurement Error in Nonlinear Models (Chapman and Hall/CRC, 2006).
32. Lin, L. I. A concordance correlation coefficient to evaluate reproducibility. *Biometrics* **45**, 255–268 (1989).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Methods

Ethical compliance. All work described here complied with all relevant ethical regulations. This work was approved by the Duke University Health System Institutional Review Board (Duke University) through protocol no. Pro00093087. For the longitudinal HIV-1 Prevention Trials Network (HPTN) Communicable Diseases (NICD), the work was approved by the University of the Witwatersrand Human Research Ethics Committee through protocol no. M201105. All participants in the AMP trials provided written informed consent. Participants were compensated to cover relevant trial participation costs for each completed study visit.

TZM-bl target cell neutralization assay. The TZM-bl target cell assay was validated using the same conditions. The assay was designed to measure infused Neutralizing Antibody (NAB) titers using the Bio-Plex instrument (Bio-Rad) using a qualified assay that was subsequently provided by Genewiz. For production of HIV-1 Env-pseudotyped virus, 293 T/17 cells (American Type Culture Collection, no. CRL-11268) were cotransfected with envelope plasmids and an envelope-defective backbone vector (pSG3delEnv). TZM-bl target cell neutralization assays were performed in two laboratories using a common standard operating procedure. Assays for HVTN 703/HPTN 081 were performed at NICD in Johannesburg, South Africa; assays for HVTN 704/HPTN 085 were performed at Duke University. Quality assurance has been established between NICD and Duke. Neutralization was measured as a function of reduction in luciferase reporter gene expression (due to the presence of serum VRC01) after a single round of HIV-1 Env-pseudotyped virus infection of TZM-bl target cells (obtained from National Institutes of Health (NIH) AIDS Research and Reference Reagent Program no. ARK-81129). Before assay, serum samples were heat inactivated at 56°C for 30 min. Autologous sera were assayed against each HIV-1 Env-pseudotyped virus at a starting dilution of 1:10 using eight three-fold serial dilutions. Neutralization titers are expressed as the reciprocal dilution of serum from a VRC01 recipient at which relative lucinescence units (RLU) were reduced by either 50% (ID₅₀) or 80% (ID₈₀) relative to virus control wells after subtraction of background RLU in cell control wells. The VRC01 drug product was used as a positive control; heat inactivation did not affect neutralization activity of the VRC01 drug product when spiked into a normal human serum sample. Data collection was performed with the Victor X Light luminometer (PerkinElmer 2030 software, instrument program v.4.00.9) at Duke up to 11 November 2020. After this date, the Glomax Navigator System luminometer was used for data collection using Glomax Navigator software (v.3.3.2.3, firmware v.4.92.0). At NICD, the PerkinElmer Victor X luminometer was used for data collection with PerkinElmer 2030 software (v.4.4).

Additional assays were performed on the VRC01 drug product (Leidos Biomedical Research, Inc./VRC-HIVMAB060-00-AB, lot no. 16-524). Neutralization titers are expressed as the concentration of the VRC01 drug product which at which RLU were reduced by either 50% (ID₅₀) or 80% (ID₈₀) relative to virus control wells after subtraction of background RLU in cell control wells. The VRC01 drug product was assayed against each HIV-1 Env-pseudotyped virus three times, at starting concentrations of 100 and 5 μg/ml, using eight three-fold serial dilution plates. HIV-1 HIV-1 Env-pseudotyped viruses were included in each plate as a positive control. VRC01 drug product stock concentrations were prepared at Duke and sent to NICD, and thus the two laboratories worked with identical material.

Binding antibody multiplex assay. Serum VRC01 IgG levels were measured on a Bio-Plex instrument (Bio-Rad) using a qualified assay that was subsequently validated using the above conditions. The assay was designed to measure infused VRC01 by its ability to bind anti-idiotypic antibody captured on fluorescent magnetic beads. This assay was derived from a standardized custom HIV-1 Luminex assay. Bio-Plex software (Bio-Plex Manager, v.6.1) provides two readouts: a background-subtracted median fluorescent intensity (MFI), where background refers to the median level (that is, a blank well containing antigen-conjugated beads run on each plate) and a concentration based on a standard curve run on the same assay plate, using a five-parameter logistic (SPL) curve fit. Each sample was run in duplicate.

Clinical-grade VRC01 was titrated to create a standard curve that was used to determine the concentrations of the diluted samples. The negative controls were CH58 (Duke Protein Production Facility) and blank beads. Samples with VRC01 concentrations <0.01 μg/ml at a dilution of 1:100 were truncated at 0.01 μg/ml for plotting purposes. Serum samples were tested at multiple dilution factors to ensure that MFI fell within the linear range of the standard curve. Reported VRC01 serum concentration was programmatically selected as the sample dilution factor that was in the well-confined range of the assay’s curves in agreement with each other, or with baseline MFI >1,000, was replaced by LLOQ2 before baseline subtraction. Nonlinear mixed-effects models were used to analyze individual-level concentrations over time, based on data up to the last visit before the last HIV-negative visit for cases and on data from all available visits for noncases, including data from six noncase participants who were purposefully sampled for concentration measurements by sampling strata defined by self-report. The sampling was restricted to noncases that did not permanently discontinue infusions. A total of 82 noncases, approximately 50% from each trial, were sampled for concentration measurements by sampling strata defined by geographic region, as described in Supplementary Table 3.

Statistics and reproducibility. In the AMP trials, participants were randomly assigned to treatment arm as described in ref. 1. Sample sizes of the two AMP trials were determined using a one-sided 0.025-level Wald control for meeting preset 70–100% agreement criteria; the same recovery threshold applied to the standard curve and spiked controls with known concentrations.

Two-phase case-control sampling design for measurement of VRC01 serum concentrations. All VRC01 recipient primary endpoint cases (HIV-1 diagnosis by crossEntre his definition of HIV-1 infection) were sampled for measurement of VRC01 serum concentrations at all blood storage visits through to HIV-1 diagnosis. Among VRC01 recipients completing the week 88 visit without HIV-1 infection diagnosis (noncases), a stratified sample of participants was selected into a subcohort for measurement of VRC01 concentrations at all blood storage visits (biweekly, every 4 weeks through to week 88, 5 days post second infusion, week 86). All sampled noncases were not likely to have used pre-exposure prophylaxis, defined for 704/985 by self-report and testing of Tenoflovir drug levels from all available dried blood spot samples that were stored at all visits, and for 703/181 by self-report. The sampling was restricted to noncases that did not permanently discontinue infusions. A total of 82 noncases, approximately 50% from each trial, were sampled for concentration measurements by sampling strata defined by randomized VRC01 dose arm cross-classified by geographic region, as described in Supplementary Table 3.

Clinical-grade VRC01 was titrated to create a standard curve that was used to determine the concentrations of the diluted samples. The negative controls were CH58 (Duke Protein Production Facility) and blank beads. Samples with VRC01 concentrations <0.01 μg/ml at a dilution of 1:100 were truncated at 0.01 μg/ml for plotting purposes. Serum samples were tested at multiple dilution factors to ensure that MFI fell within the linear range of the standard curve. Reported VRC01 serum concentration was programmatically selected as the sample dilution factor that was in the well-confined range of the assay’s curves in agreement with each other, or with baseline MFI >1,000, was replaced by LLOQ2 before baseline subtraction. Nonlinear mixed-effects models were used to analyze individual-level concentrations over time, based on data up to the last visit before the last HIV-negative visit for cases and on data from all available visits for noncases, including data from six noncase participants who were purposefully sampled for the last visit before week 88, to keep the laboratory blinded to the case-control status of the samples (because all noncases would have had the full course of time points until week 88).

VRC01 PK following IV infusion, with a more rapid decline in the distribution phase and slower decline in the elimination phase, was described by a
two-compartment disposition model with first-order elimination from the central compartment. The PK model was parametrized in terms of CL, Vf, Q, Vc, and Vp, denoting clearance from the central compartment (CL), volume of the central compartment (Vf), intercompartmental distribution clearance (Q), and volume of the peripheral compartment (Vc), respectively. An exponential between-individual random effect for CL, Vf, Q, Vc, and Vp, as well as an exponential interindividual random effect (that is, interoccasion variability) for CL and Vf, were considered based on patterns observed in the data. In the final popPK model, trial (HVTN 704/HPTN 085 or HVTN 703/HPTN 081) and body weight were included as a predictor of Vf and CL, respectively. Further details are described in refs. 43 and references therein. Each VRC01 recipient’s concentrations on a daily grid, including at the estimated time of infection for cases, were estimated from the final popPK model. The point-wise 95% prediction interval of each daily grid concentration was computed as the 2.5th and 97.5th percentiles of the estimated concentrations of >1,000 parametric bootstrap samples, generated via resampling of the random effects and residual errors from the final popPK model of the observed concentrations. Based on each bootstrap sample of the concentration data at the observed time points, the popPK model was refit and daily grid concentrations were estimated for each bootstrap dataset.

**Serum neutralization titer associated with VRC01 prevention efficacy.** Because knowing the exact day of HIV-1 acquisition (and hence VRC01 concentration on the day of acquisition) is unattainable in a clinical trial setting, for Fig. 3 PT80 was calculated as the median observed VRC01 concentration at all mid-infusion visits across all noncases in case-control samples (19.6 μg ml⁻¹ measured by BAMA), divided by the IC80 of the VRC01 drug product against the acquired virus (n = 162 HIV-1 cases) in both VRC01 and placebo arms from the AMP trials. The median concentration was computed based on the n = 82 noncase VRC01 recipients sampled for PK modeling from both dose arms and both trials. Note that the neutralization sieve analysis for Fig. 3 could not use individual-specific concentration estimates as the sieve method was designed to assess how PE is dependent on a virus feature (for example, IC80), not on a feature that depends on both host and virus. The analysis was performed similarly for Extended Data Fig. 5, except that PT80 and IC80 were used in place of PT80 and IC80, respectively.

The NHP estimated protection curves in Fig. 3 were calculated from logistic regression using day-of-challenge PT80 from meta-analysis of each of the datasets described in the figure (and similarly in Extended Data Fig. 5 using day-of-challenge PT80).

In Fig. 4, PT80 was calculated as the estimated serum concentration for each of the 82 noncases in the case-control sample at each day of follow-up, divided by the IC80 of the VRC01 drug product against the viruses acquired by placebo recipients (n = 19 IC80 < 1 μg ml⁻¹; n = 10 IC80 < 3 μg ml⁻¹; n = 35 IC80 > 3 μg ml⁻¹). These serum concentrations in daily grid over the trial follow-up period (from day 1 to week 80 visit) were estimated based on popPK modeling of observed VRC01 concentrations for each of the 82 VRC01 recipient noncases sampled for PK modeling. Analyses were performed similarly for Extended Data Fig. 6, except that PT80 and IC80 were used in place of PT80 and IC80, respectively.

VRC01 serum concentration correlates analysis. The population for analysis included all AMP participants from either trial assigned to one of the two VRC01 dose arms. A Cox model with enrollment as the time origin was used to assess the association of VRC01 serum concentration (included as a time-dependent covariate on a daily grid) with the instantaneous hazard of HIV-1 acquisition, which uses empirical inverse probability sampling weights to accommodate the association of VRC01 serum concentration with the instantaneous hazard of HIV-1 acquisition.

Calculations to support the premise that the VRC01 serum concentration correlate of risk result is consistent with the observed VRC01 dose effect on HIV-1 acquisition. The 30 mg kg⁻¹ arm had 23% improved efficacy compared with the 10 mg kg⁻¹ arm, as follows:

PE of 29% and 8% (23%) = (1 − (1 − 0.29) / (1 − 0.08)) x 100%.

PT80 against autologous acquired virus analysis. The ‘marker method’ of Gilbert et al. was applied to assess whether PT80 against the autologous acquired virus at acquisition tended to be low compared with PT80 against placebo viruses, assuming that exposures that had occurred uniformly over the 80-week follow-up period. The results are shown in Fig. 5b. For each VRC01 case, the PT80 against their autologous acquired virus at acquisition was calculated in three steps: (1) estimation of the time–concentration curve for each case from a popPK model over a daily grid spanning all possible dates of HIV-1 acquisition; (2) averaging of (log-transformed) daily concentrations weighted by the Bayesian posterior distribution of daily probability of HIV-1 acquisition; and (3) division of the aggregated concentration in step 2 by the IC80 of the VRC01 drug product against their acquired virus (Huang et al., approach 2). For each VRC01 recipient noncase, we calculated their median estimated VRC01 serum concentration over follow-up (estimated on a daily grid from day 1 to the week 80 visit from the PK model), which represents the most typical VRC01 concentration that would occur at the time of HIV-1 exposure. We then divided this median VRC01 serum concentration by the geometric mean VRC01 IC80 of the viruses acquired by placebo recipients in the AMP trial, which is a typical value of PT80 against a given exposing virus assuming that HIV-1 exposure follows a uniform distribution over the trial follow-up period (Extended Data Fig. 2).

The geometric mean PT80 values among cases and the geometric mean of those typical PT80 values among noncases were calculated with the standard errors estimated by the bootstrap procedure described earlier for daily grid serum concentrations. From these estimates, Wald-based 95% CIs were computed; bootstrap-based percentiles on a grid of coverage levels were inverted to compute a two-sided P-value. The analysis was performed for the AMP trials pooled, for the two VRC01 dose arms pooled and for each individual VRC01 dose arm.

Analyses were performed similarly for Extended Data Fig. 7, except that PT80 and IC80 were used in place of PT80 and IC80, respectively.

Neutralization coverage of combination bnAbs. In Fig. 6a–d, steady state of a reference bnAb concentration is considered to reach the steady state level of the rate of bnAb input is equal to the rate of bnAb elimination and consequently serum concentration–time levels remain the same over continuing cycles. For each single bnAb, a virus exposure was considered neutralized (covered) if PT80 (calculated as PK modeled concentration divided by virus IC80) exceeded 200. In Extended Data Fig. 8, this threshold was defined as when PT80 (calculated as PK modeled concentration divided by virus IC80) exceeded 200. Coverage was computed assuming that exposures to HIV-1 follow a uniform distribution over the 16- or 24-week period post-infection that is considered.

Predicted prevention efficacy of combination bnAbs. The prediction of PE for the triple-bnAb combination, PGDM1400L5+PGT1211S+VRC07-523LS, was carried out in four steps. First, serum concentration of each single bnAb over time (16 or 24 weeks in steady state) was predicted on the population level by using a humanized bioavailability model. Second, each serum concentration was inverse transformed to compute the two-sided P-value for a fixed level of protection twofold higher in human than in NHP set (C that is, shifting the NHP set C to the right by twofold).

Distribution of HIV-1 acquisition date. Point estimates of HIV-1 infection time (calendar date) were calculated by blinded analysis for each participant, using the median of the Bayesian posterior distribution. This was computed by independent combination of the estimated posterior distributions of infection date after conditioning on: (1) diagnostic curves, as described in Grebe et al. for the infection dating tool method, by a combination of window period distributions (defined in Pilcher et al.) of last negative and first positive HIV-1 diagnostic tests; and (2) the distribution of pairwise Hamming distances (as described in Giorgi et al. for the Poisson Fitter method), calculated from nucleotide sequence data obtained from the first available HIV-positive samples, following the steps listed in Supplementary Note 2 (i–vii) for sequence-based timing estimates. We also employed Bayesian posterior estimates of infection time by day to assess the probability that the infection occurred in the first 4 weeks after an infusion. These were used to describe 95% credible regions for the time since infection in the process described in Supplementary Note 2.

Our approach employed Bayesian procedures to combine independent inputs from three data sources: diagnostics timing estimators, gag-pol-based sequence timing estimators and rev—env—nef-based sequence timing estimators. The probabilities of HIV-1 infection time were fit using the frequentist and Bayesian approaches implemented in Poisson Fitter by employing the steps described below, with the aim of optimizing the estimate of infection time. These Poisson Fitter estimates were then converted to corresponding Bayesian Poisson process regression models to yield probability assessments for incorporation into downstream analyses, including both point estimates and uncertainty intervals across the Bayesian and frequentist implementations. When the two sequenced regions yielded distinct time estimates (that is, the 95% posterior credible intervals did not overlap), the gag-pol region was chosen for the final time estimate since it...
does not encode proteins targeted by the VRC01 bmAb, and therefore the rates of evolution over this region of the viral genome may be impacted to a lesser extent by targeted selection.

The process of running Poisson Fitter 2.0 included production of separate timing estimates for each curated first time point alignment for the two sequenced regions and then integrating the outputs downstream. Only the first time point sequences were used for the primary analysis, except for cases in which the first time point yielded fewer than five sequences; in such cases, the second available time points were analyzed instead. For each sequenced sample, we created Poisson Fitter estimates and then corresponding Bayesian posterior estimates of time since infection, given (1) gog-pol and (2) rev–env–nef region alignments. The process is described in further detail in Supplementary Note 2.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The data underlying the findings of this manuscript are publicly available at the public-facing HVTN website (https://atlas.scharp.org/cpas/project/HVTN%20Public%20Data/begin.view?). All individual participant data have been deidentified.

The GenBank accession numbers for the HIV-1 Env clones used in the TZM-bl target cell neutralization assay are: HVTN 704/HPTN 085 sequences, ON98014–ON980967; HVTN 703/HPTN 081 sequences, ON890939–ON891092.

Code availability

Code implementation methods described in Gilbert et al.13 are publicly available at http://faculty.washington.edu/peterg/programs.html? All other code implementing the methods used to generate the figures and tables of this work is available at Github (https://github.com/HVTN-SDMC/AMP_NeutTiterBiomarker).

Instructions for installation and use are given in the accompanying README file.

References

34. Montefiori, D. C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485, 395–405 (2009).
35. Li, M. et al. Human immunodeficiency virus type 1 Env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108–10125 (2005).
36. Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131–146 (2014).
37. Tomaras, G. D. et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virus-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82, 12449–12463 (2008).
38. Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012).
39. Mayer, K. H. et al. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: results of a phase 1 randomized trial. PLoS Med. 14, e1002435 (2017).
40. Nicely, N. J. et al. Structural analysis of the unmuted ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV141 vaccine efficacy trial vaccinee. EbioMedicine 2, 713–722 (2015).
41. Pollara, J. et al. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J. Virol. 88, 7715–7726 (2014).
42. Gilbert, P. B. et al. Basis and statistical design of the passive HIV-1 Antibody Mediated Prevention (AMP) test-of-concept efficacy trials. Stat. Commun. Infect. Dis. https://doi.org/10.1515/scid-2016-0001 (2017).
43. Huang, Y. et al. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. EbioMedicine 64, 103203 (2021).
44. Huang, Y. et al. Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. Mabs 9, 792–800 (2017).
45. Lin, D. Y. On fitting Cox’s proportional hazards models to survey data. Biometrika 87, 57–74 (2000).

46. Pilcher, C. D. et al. A generalizable method for estimating duration of HIV infections using clinical testing history and HIV test results. AIDS 33, 1231–1240 (2019).

Acknowledgements

This work was supported by the NIH through award nos. UM1 AI0668614 (D.H.B., L.C. and G.D.T.), UM1 AI0668635 (P.B.G. and Y.H.), 4 R37 AI054165-21 (P.B.G.), UM1 AI066818, UM1 AI066819 (M.S.C.), UM1 AI066813, UM1 AI066817, P30 AI027757 (J.I.M.), P30 AI064518 (G.D.T.) and K25 AI1155244 (D.B.R.); and by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases and the South African Medical Research Council (L.M.). This work was also supported, in whole or in part, by the Bill & Melinda Gates Foundation (CAYD grant nos. OPP1146996 and INV-036842 (B.K.)). Under the conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the author-accepted manuscript version that might arise from this submission. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. We thank the trial participants and staff, study teams and community members of the clinical research sites. We also thank the HVTN Core staff, the Hutchinson Centre Research Institute of South Africa staff, the Statistical Center for HIV/AIDS Research & Prevention, the HVTN Laboratory Center, the DAIDS/NIAD Vaccine Research Program and Pharmaceutical Affairs Branch and Triclinium Clinical Development.

Author contributions

P.B.G. and Yunda Huang contributed equally to this work. D.C.M. and L.M. also contributed equally to this work. P.B.G., Yunda Huang, A.C.d.C., S.K., M.S.C., L.C., D.C.M. and L.M. conceived the study. P.B.G., Yunda Huang, A.C.d.C., C.A.M., E.E.G., B.K., P.T.E., R.R., M.J., E.R., N.K., Ying Huang, N.N.M., T.H., P.K., V.B., H.K., R.M., A.E., E.D., C.W., W.F., H.T., K.E.S., J.H., C.B., K.C., G.D.T., C.W., J.I.M., L.C.M. and D.C.M. and L.M. developed the methodology used in the study. P.B.G., Yunda Huang, A.C.d.C., C.A.M., E.E.G., B.K., P.T.E., R.R., M.J., E.R., N.K., Ying Huang, D.C.M. and L.M. performed analyses. P.B.G., S.K., N.N.M., T.H., P.K., V.B., H.K., R.M., A.E., E.D., C.W., W.F., H.T., K.E.S., J.H., C.B., K.C., G.D.T., C.W., J.I.M., L.C.M. and D.C.M. contributed to validated. P.B.G., Yunda Huang, A.C.d.C., C.A.M., E.E.G., B.K., P.T.E., R.R., M.J., E.R., N.K., Ying Huang, D.C.M. and L.M. performed analyses. P.B.G., S.K., N.N.M., T.H., P.K., V.B., H.K., R.M., A.E., E.D., C.W., W.F., H.T., K.E.S., J.H., C.B., K.C., G.D.T., C.W., J.I.M., L.C.M. and D.C.M. conducted research and/or performed experiments. P.B.G., S.K., B.K., D.H.B., G.D.T., P.A., M.E.S., N.G.S., J.S., C.G., J.M., C.W., J.H., M.S.C., J.I.M., L.C.M. and D.C.M. conducted research and/or performed experiments. P.B.G., S.K., B.K., D.H.B., G.D.T., P.A., M.E.S., N.G.S., J.S., C.G., J.M., C.W., J.H., M.S.C., J.I.M., L.C.M. and D.C.M. contributed to visualization/data presentation. P.B.G., Yunda Huang, B.K., P.T.E., G.D.T., M.S.C., L.C., D.C.M. and L.M. acquired funding. P.B.G. wrote the original draft. Ying Huang, S.K., L.N.C., D.C.M. and L.M. also contributed to writing. All coauthors reviewed and edited the manuscript and provided approval of the final version.

Competing interests

The authors declare no competing interests.

Additional information

Extended data is available for this paper at https://doi.org/10.1038/s41591-022-01953-6.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41591-022-01953-6.

Correspondence and requests for materials should be addressed to Peter B. Gilbert.

Peer review information Nature Medicine thanks Giuseppe Pantaleo and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editors: Alison Farrell and Saheli Sadanand, in collaboration with the Nature Medicine team.

Reprints and permissions information is available at www.nature.com/reprints.
Extended Data Fig. 1 | Estimated protection curves (calculated from logistic regression) by day-of-challenge predicted serum ID80 titer (PT80) against the challenge SHIV, shown by bnAb class and by challenge SHIV, in subsets of N = 274 non-human primates (NHPs) that received a single bnAb and underwent SHIV challenge. Day-of-challenge PT80 was calculated as day-of-challenge bnAb concentration divided by IC80 against the challenge SHIV, where PT80 values < 2 were set to 1. Only neutralization titer data obtained by the TZM-bl target cell assay were included. The bnAb and SHIV challenge description of each subset is shown in the lower right legend. **a)** Only CD4 binding site-targeting bnAbs, separated by challenge SHIV; **b)** All bnAbs excluding MPER-targeting bnAbs, separated by challenge SHIV. The figure shows that the estimated protection curve for SF162P3 challenge is an outlier.
Extended Data Fig. 2 | Estimated serum VRC01 concentration (filled black dot) at the estimated time of infection (median of the Bayesian posterior distribution of infection time) since last infusion in all primary endpoint HIV-1 cases, by randomization arm in each trial. (a) HVTN 704/HPTN 085 (n = 36 cases in Control, n = 31 cases in the 10 mg/kg arm and n = 25 cases in the 30 mg/kg arm) with an additional 3 cases not shown in the 30 mg/kg panel due to estimated infection time > 10 weeks since last infusion, and 7 and 1 case(s) not shown in the Control and 10 mg/kg panels, respectively, due to estimated infection time ≤ 0 or not being available. (b) HVTN 703/HPTN 081 (n = 27 cases in Control, n = 28 cases in the 10 mg/kg arm and n = 17 cases in the 30 mg/kg arm) with an additional 2 and 2 cases not shown in the Control and 30 mg/kg panels, respectively, due to estimated infection time ≤ 0 or not being available. For each VRC01-recipient case, vertical error bars represent the 90% prediction interval around the estimated serum VRC01 concentration at the estimated infection time (center of the error bars), accounting for variabilities in both the estimation of the infection time and the estimation of concentration are displayed for each VRC01-recipient case. The former uncertainty is incorporated via resampling infection time from the Bayesian posterior distribution of infection time and the latter is incorporated via variabilities estimated based on the final popPK model for the daily grid concentrations at each given estimated infection time (see Methods). The solid black line represents the median and the shaded area represents bands covered by the 2.5th and 97.5th percentiles of the estimated concentrations over time within each dose group using the median body weight of participants in the case-control cohort, accounting for between-individual variabilities estimated based on the final popPK model.
Extended Data Fig. 3 | Predicted serum ID80 titer (PT80)-predicted prevention efficacy over time in the context of viruses circulating in each of the AMP trials for the bnAb regimen PGDM1400LS + PGT121LS + VRC07-523LS at 20 + 20 + 20 mg/kg or 40 + 40 + 40 mg/kg, delivered intravenously every 24 weeks and evaluated in study cohorts of the same sizes as the AMP trials. Solid line: median. Shaded area: 95% prediction interval. Predictions made under the scenario that PGT121LS and PGDM1400LS have 2.5-times higher half-lives as PGT121 and PGDM1400, using observed serum concentration data\(^1\). The viruses circulating in each trial are: (a) the m = 47 viruses acquired by n = 29 703/081 (Sub-Saharan Africa) placebo recipients; (b) the m = 70 viruses acquired by n = 35 704/085 (Americas + Switzerland) placebo recipients. The PT80 of the triple-bnAb regimen was calculated using the Bliss-Hill interaction model of the individual bnAb PT80 titers\(^10\).
Extended Data Fig. 4 | Agreement between predicted vs experimental serum neutralization ID50 titer. Sera from samples from the last visit (and for a subset from the last two last visits) prior to the first positive HIV-1 RNA PCR test were assayed against autologous isolates from 64 VRC01 recipients who acquired HIV-1 infection (cases) (90 isolates, 164 titers). Predicted serum ID50 titer (PT50) values are plotted against the experimental ID50 for each sample and each isolate [Lin's concordance correlation coefficient $^3=0.92$ (95% CI 0.80 to 0.97)]. PT50 was calculated as popPK model-predicted concentration divided by IC50. Thirty-two of 164 experimental ID50 titers were below the limit of detection when the PT50 was greater than 10 (range 10.2 to 36.3). Zero of 164 experimental ID50 titers was at or above the limit of detection when the PT50 was less than 10. Dashed horizontal and vertical lines at a value of 10 show the experimental ID50 limit of detection; concordance of predicted vs. experimental values above vs. below 10 was 132 of 164 (80.5%).
Extended Data Fig. 5 | Estimated prevention efficacy (PE) by predicted serum ID50 titer (PT50) to the autologous acquired virus in the AMP trials and in non-human primate (NHP) studies. a) Estimated PE by PT50 to the acquired virus in AMP (black line), compared to the protection curve in three different sets of NHP (blue, mustard, and green lines). b) PT50 associated with 50% PE, 75% PE, and 90% PE, for the AMP trials and for each of the three sets of NHP. Set A: N = 274 NHPs that received a single bnAb followed by SHIV challenge, bnAb titer data from all neutralization assays; Set B: only the NHPs in Set A that received a CD4 binding site-targeting bnAb, excluding all that were challenged with SF162P3, and only including bnAb titer data from the TZM-bl target cell assay; and Set C: all NHPs in Set A, but excluding those that received an MPER-targeting bnAb and excluding all that were challenged with SF162P3, and only including bnAb titer data from the TZM-bl target cell assay.
Extended Data Fig. 6 | Distributions of predicted serum ID50 titers (PT50s) against viruses acquired by placebo recipients, within each virus neutralization IC50 sensitivity category. Distributions of predicted serum ID50 titers (PT50s) against viruses acquired by placebo recipients, within each virus neutralization IC50 sensitivity category. Approach 2 of Huang et al. was used to calculate PT50 against a given virus by dividing the population PK model-predicted VRC01 serum concentration by the IC80 of the VRC01 drug product against the virus. The distributions are for PT50s of the 82 non-cases in the case-control cohort calculated at each day over the 80-week follow-up against each of the viruses acquired by placebo recipients. On the y-axis, each filled black dot is a point estimate of prevention efficacy against viruses in the specified sensitivity category and the vertical lines are 95% confidence interval estimates as previously reported. The downward arrowhead indicates a value below the y-axis lower limit. On the x-axis, each filled black dot is the median PT50 against viruses acquired by placebo recipients, within each virus neutralization IC50 sensitivity category; the horizontal rectangles extend through the interquartile range and on each side of the boxplot is a kernel density estimation of the distribution shape of the PT50.
Extended Data Fig. 7 | See next page for caption.
Extended Data Fig. 7 | Predicted serum ID50 titers (PT50s) to autologous acquired viruses at HIV-1 acquisition among VRC01 arm cases, and to placebo-recipient acquired viruses among VRC01 arm non-cases. (a) Violin plots for VRC01-recipient cases vs. non-cases, where Approach 2 of Huang et al. was used to calculate PT50 at a given time point against a given virus. For each VRC01-recipient case, PT50 at the estimated date of HIV-1 acquisition (red dots) was calculated as the estimated VRC01 concentration at acquisition divided by the VRC01 drug product IC50 against the autologous virus. For each of the 82 sampled VRC01-recipient non-cases, PT50 at each day of follow-up against each placebo-recipient acquired virus was calculated as the estimated VRC01 concentration divided by the VRC01 drug product IC50 against the virus (blue dots). The lower bound, horizontal line, and upper bound of the vertical rectangle boxplots show the 25th, 50th, and 75th percentiles, respectively. On each side of the boxplot is a kernel density estimation of the distribution shape of the PT50. (b) By VRC01 dose arm and across dose arms pooled: geometric mean PT50 at HIV-1 acquisition in VRC01-recipient cases against the autologous acquired virus, geometric mean PT50 in VRC01-recipient non-cases (their individual-specific medians over follow-up) to placebo-recipient acquired viruses, and their ratio. Error bars represent 95% confidence intervals.
Extended Data Fig. 8 | See next page for caption.
Extended Data Fig. 8 | (A, B) Neutralization coverage (defined by PT50 > 600) (averaged to viruses) and (C, D) geometric mean predicted serum ID50 (PT50) titer against viruses circulating in each of the AMP trials for the bnAb regimen PGT121LS + PGDM1400LS + VRC07-523LS 20 + 20 + 20 mg/kg delivered intravenously every 16 weeks and evaluated in study cohorts of the same sizes as the AMP trials. In (A, B), the tables below each plot provide the neutralization coverage averaged to viruses and averaged over the given time frame. A virus exposure was considered covered by 1-active, 2-active, or 3-active bnAbs if the coverage threshold (PT50 > 600) is achieved by at least 1, at least 2, or all 3 bnAbs. All predictions were made under the scenario that PGT121LS and PGDM1400LS have 2.5-times higher half-lives as PGT121 and PGDM1400, based on modeling of observed serum concentration data of PGT121 and PGDM140018,19. For each bnAb regimen, geometric mean PT50 at each time-point was calculated as the geometric mean of predicted serum concentration across bnAb recipients at each time-point during steady state (simulated based on population PK modeling of each bnAb as described in Methods) divided by the geometric mean of bnAb drug product IC50 across viruses circulating in the designated AMP trial, that is (a, c) the m = 47 viruses acquired by n = 29 703/081 (Sub-Saharan Africa) placebo recipients; (b, d) the m = 70 viruses acquired by n = 35 704/085 (Americas + Switzerland) placebo recipients. The PT50 of the triple-bnAb regimen was calculated using the Bliss-Hill interaction model of the individual bnAb PT50 titers10.
Extended Data Fig. 9 | Predicted serum ID50 titer (PT50)-predicted prevention efficacy over time in the context of viruses circulating in each of the AMP trials for the bnAb regimen PGDM1400LS + PGT121LS + VRC07-523LS at 20 + 20 + 20 mg/kg or 40 + 40 + 40 mg/kg, delivered intravenously every 16 weeks and evaluated in study cohorts of the same sizes as the AMP trials. Solid line: median. Shaded area: 95% prediction interval. Predictions made under the scenario that PGT121LS and PGDM1400LS have 2.5-times higher half-lives as PGT121 and PGDM1400, using observed serum concentration data18,19. The viruses circulating in each trial are: (a) the m = 47 viruses acquired by n = 29 703/081 (Sub-Saharan Africa) placebo recipients; (b) the m = 70 viruses acquired by n = 35 704/085 (Americas + Switzerland) placebo recipients. The PT50 of the triple-bnAb regimen was calculated using the Bliss-Hill interaction model of the individual bnAb PT50 titers10.
Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a  Confirmed

☐ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement

☐ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly

☐ The statistical test(s) used AND whether they are one- or two-sided

Only common tests should be described solely by name; describe more complex techniques in the Methods section.

☐ A description of all covariates tested

☐ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons

☐ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) and variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)

☐ For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted. Give P values as exact values whenever suitable.

☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings

☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes

☐ Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection
Clinical data were collected through Case Report Forms (CRFs) that are part of an electronic data capture (EDC) system or through electronic patient-reported outcome (ePRO). Laboratory data were collected at central research labs.

For Duke, from the start of the study a luminometer called the Victor X Light was used for data collection using The PerkinElmer 2030 software (Instrument Program version = 4.00.05) which is a 32-bit application running under Windows 7. Starting November 11th 2020, after IQ/OQ, a new luminometer was used called Glomax Navigator System using Glomax Navigator software (software version 3.2.3, firmware version 4.92.0). For NICO, for the duration of the study we used the PerkinElmer Victor X Luminometer for data collection using the PerkinElmer 2030 software.

For the BAMA assay, Bioplex software was used for data collection (Bioplex Manager, version 6.1).

Data analysis
Code implementing methods described in Gilbert et al. 2019 Stat Med. is publicly available at http://faculty.washington.edu/peterpg/programs.html? All other code implementing the methods to generate the figures and tables of this work is available at Github (https://github.com/HVTN-SDMC/AMP_NeutTiterBiomarker). Instructions for installation and use are given in the accompanying README file.

Estimation of HIV-1 infection timing also used the LANL Highlighter tool [http://www.hiv.lanl.gov/cgi-bin/HIGHLIGHT/highlighter.cgi] (last modified: Nov 3, 2017), the LANL tool RAPR [https://www.hiv.lanl.gov/content/sequence/RAPR2017/rap.html] (last modified: Dec 9, 2021), and the LANL tool Hypermut [https://www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html] (last modified: Dec 22, 2014).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. Github). See the Nature Portfolio guidelines for submitting code & software for further information.
Data

Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The data underlying the findings of this manuscript are publicly available at the public-facing HTVN website (https://atlas.scharp.org/cpas/project/HTVN%20Public%20Data/BeginView). All individual participant data have been de-identified. The GenBank accession numbers for the HIV-1 Env clones used in the TZM-bl target cell neutralization assay are: HTVN 704/HPTN 085 sequences, ON980814 - ON980967; HTVN 703/HPTN 081 sequences, ON980939 - ON981092.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences
- Behavioural & social sciences
- Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-list.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size
Two-phase case-control sampling design for measuring VRC01 serum concentrations: All VRC01 recipient primary endpoint cases [HIV-1 diagnosis by the Week 80 visit, same definition as in 8] were sampled for measurement of VRC01 serum concentrations at all blood storage visits through to HIV-1 diagnosis. Among VRC01 recipients completing the Week 88 visit without HIV-1 infection diagnosis (non-cases), a stratified sample of participants was selected into a subcohort for measurement of VRC01 concentrations at all blood storage visits [baseline, every 4 weeks through Week 80, 5 days post second infusion, Week 88]. All sampled non-cases were not likely to have used PEP, defined for 704/085 by self-report and testing of tenofovir drug levels from all available dried blood spot samples that were stored at all visits, and for 703/081 by self-report. The sampling was stratified to non-cases that did not continuously discontinue infusions. A total of 92 non-cases, approximately half and half from each trial were sampled for concentration measurements by sampling strata defined by randomized VRC01 dose arm cross-classified by geographic region, as described in Supplementary Table 1.

Data exclusions
There are pre-established exclusion criteria applied to all data in the form of an assay SOP QC checklist, any assays that did not pass the checklist criteria were repeated.

Replication
This study utilized two sets of neutralizing antibody assay results, one set was generated with a clinical lot of VRC01 and a second set was generated with autologous serum samples. Assays with the clinical lot of VRC01 were performed three times, where each time the samples were tested in duplicate wells. The three titer values were averaged. Assays with autologous serum samples were performed once using duplicate wells. VRC01 drug product was used as a positive control in each assay run. The assay has been formally validated for accuracy, sensitivity, specificity, precision, linearity, range and robustness. For in vitro neutralization measurements (IC50 or IC90), duplicate values for assays that scored at least 40% neutralization must have agreed within 30% to have passed quality control.

The BAMA assay was qualified and validation experiments using the same assay conditions were complete at the time the study was performed. Additionally, qualified BAMA derived serum VRC01 concentrations demonstrated excellent concordance with true VRC01 concentration in a blinded HIV-1 seronegative serum spiked QC reference panel [Supplementary Figure 1]. General measures to verify the reproducibility of the experimental findings included: 1) Confirmation of reported serum concentration across dilution factor or assays, 2) tracking of VRC01 controls through use of historical Levey-Jennings charts and 3) titration of serum samples to obtain multiple dilutions within the linear range of the assay (see Methods). All attempts at replication were successful.

Randomization
In the AMP trials, participants were randomly assigned to treatment arm as described in Corey and Gilbert et al. 2011 NEJM. As described in that reference, the randomization sequence was obtained by computer-generated random numbers and provided to each CRS through a Web-based randomization system. The randomization was done in blocks to ensure balance across arms. At each institution, the pharmacist with primary responsibility for dispensing study products was charged with maintaining security of the treatment assignments (except in emergency situations as specified in the SPP).

Blinding
Point estimates of HIV-1 infection time [calendar date] were calculated by blinded analysts for each participant, using the median of the Bayesian posterior distribution.
For BAMA measurements, nonlinear mixed effects models were used to analyze individual-level concentrations over time, based on data up to the visit prior to the last HIV negative visit for cases and data from all available visits for non-cases, including data from 6 non-case participants who were purposefully sampled with the last visit prior to week 88 to keep the lab blinded to the case-control status of the samples (because all non-cases would have the full course of timepoints until week 88). Laboratory staff conducting the TZM-bl target cell assays were blinded to group allocation during data collection and analysis.
Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

| n/a | Involved in the study |
|-----|------------------------|
| ☐   | Antibodies             |
| ☒   | Eukaryotic cell lines  |
| ☐   | Palaeontology and archaeology |
| ☐   | Animals and other organisms |
| ☒   | Human research participants |
| ☐   | Clinical data          |
| ☐   | Dual use research of concern |

### Methods

| n/a | Involved in the study |
|-----|------------------------|
| ☒   | ChIP-seq               |
| ☐   | Flow cytometry         |
| ☒   | MRI-based neuroimaging |

### Antibodies

**Antibodies used**
The VRC01 drug product stock concentrations were prepared at Duke and sent to the NICD; thus the two laboratories worked with identical material. CHS8 (Duke Protein Production Facility) (Nicely et al. 2015 EBioMedicine, Pollara et al. 2014 J Virol).

**Validation**
The VRC01 drug product was used as a positive control; heat inactivation did not affect the neutralization activity of the VRC01 drug product when spiked into a normal human serum sample. The VRC01 drug product was assayed against each HIV-1 Env-pseudotyped virus three times at starting concentrations of 100 µg/ml and 5 µg/ml using eight three-fold serial dilutions in duplicate. HIV-1 PVO.4 Env-pseudotyped virus was included in each assay as a positive control to confirm the integrity of the VRC01 drug product. The assay has been formally validated for accuracy, sensitivity, specificity, precision, linearity, range and robustness.

### Eukaryotic cell lines

**Policy information about cell lines**

**Cell line source(s)**

293T/17 cells were obtained from American Type Culture Collection (Cat#CRL-11268). TZM-bl cells were obtained from the NIH AIDS Research and Reference Reagent Program (Cat#ARP-8129).

**Authentication**

293T/17: No additional authentication procedures were conducted except to confirm the morphology and adherence patterns of the cells under the microscope. The cells also performed as expected in virus growth assays. TZM-bl: No additional authentication procedures were conducted except to confirm the morphology and adherence patterns of the cells under the microscope. Obtaining expected results in our external proficiency programme was also part of the authentication.

**Mycoplasma contamination**

We confirmed on a regular basis that all cell lines tested negative for mycoplasma.

**Commonly misidentified lines (See lclac register)**

None used.

### Human research participants

**Policy information about studies involving human research participants**

**Population characteristics**

Demographic characteristics of the participants in the AMP trials are provided in Table 1 of Corey and Gilbert et al. NEJM (2021).

**Recruitment**

Participant recruitment for the AMP trials is detailed in Edupuganti et al. 2021 JAMA 1;87(1):671-679. “Community engagement began 6 months before study opening. Community stakeholder meetings with diverse audiences were held regionally and nationally. Recruitment and retention were considered major challenges for the AMP studies, given the 10 IV infusions and 2-year (or 104 week) duration of study participation. Print materials and animated videos were developed in multiple languages. Internet-based recruitment (through social media, Craigslist, dating Web sites, and others), face-to-face outreach by recruiters, and referrals from other participants were some of the key strategies that were used for recruitment. Regional protocol-specific Web sites (www.ampsstudy.org) were developed to enhance education of potential study participants and link them to local CRSS.” We are not aware of any potential self-selection bias or other biases that may impact results.

**Ethics oversight**

All work described here complied with all relevant ethical regulations. This work was approved by the Duke University Health System Institutional Review Board (Duke University) through protocol ID Pro00093087. For the NICD the work was approved by the University of the Witwatersrand Human Research Ethics Committee through protocol M201105. All participants provided written informed consent.
Clinical data

Policy information about clinical studies
All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

| Clinical trial registration | ClinicalTrials.gov numbers NCT02716675 and NCT02568215 |
|-----------------------------|----------------------------------------------------------|
| Study protocol              | Full trial protocols are available with the primary publication: https://www.nejm.org/doi/full/10.1056/NEJMoa2031738 |
| Data collection             | Enrollment is described in the primary publication: https://www.nejm.org/doi/full/10.1056/NEJMoa2031738  **For the AMP trials, between April 6, 2016, and October 5, 2018, a total of 2699 participants were enrolled in HIVTN 704/HPTN 085, and between May 17, 2016, and September 20, 2018, a total of 1924 participants were enrolled in HIVTN 703/HPTN 081.** For data collection: All VRC01 recipient primary endpoint cases [HIV-1 diagnosis by the Week 80 visit; same definition as in 8] were sampled for measurement of VRC01 serum concentrations at all blood storage visits through to HIV 1 diagnosis. Among VRC01 recipients completing the Week 88 visit without HIV-1 infection diagnosis (non-cases), a stratified sample of participants was selected into a subcohort for measurement of VRC01 concentrations at all blood storage visits [baseline, every 4 weeks through Week 80, 5 days post second infusion, Week 88]. |
| Outcomes                    | Described in the primary publication: https://www.nejm.org/doi/full/10.1056/NEJMoa2031738 This manuscript does not report primary, secondary outcomes |